DAFNA Capital Management LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+19,194
(19.8%)
New positions
9
Sold out positions
9
Turnover %
13.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| AMPE | 7,288 | 240.1% |
| DERMA SCIENCES INC | 4,262 | 690.8% |
| *BIOTA PHARMACEUTIALS INC | 3,088 | 225.2% |
| GLMD | 2,318 | NEW |
| ATRC | 2,209 | 25.9% |
| Novadaq Technologies | 1,188 | 25.4% |
| KERYX BIOPHARMACEUTICALS | 1,134 | 198.9% |
| NXSTAGE MEDICAL INC | 1,052 | 27.4% |
| PLX | 813 | 17.7% |
| *CYTRX CORP | 785 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| GIVEN IMAGING | -4,702 | -100.0% |
| VENAXIS INC | -1,071 | -84.8% |
| ONCOGENEX PHARMACEUTICALS IN | -928 | -100.0% |
| Histogen Inc. | -875 | -100.0% |
| DISCOVERY LABORATORIES INC N | -570 | -4.4% |
| DYAX CORP | -569 | -100.0% |
| *DYNAVAX TECHNOLOGIES CORP | -568 | -100.0% |
| STXS | -422 | -6.7% |
| PHARMACYCLICS INC | -404 | -3.5% |
| BAXANO SURGICAL INC COM | -340 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|